Advertisement
Screener

60 DEGREES PHARMACEUTICALS, INC. (SXTP) Noncash or Part Noncash Acquisition, Intangible Assets Acquired

2.9 / 5 stars · 18/31 Roast Me

60 DEGREES PHARMACEUTICALS, INC. Noncash or Part Noncash Acquisition, Intangible Assets Acquired

60 DEGREES PHARMACEUTICALS, INC. (SXTP) reported Noncash or Part Noncash Acquisition, Intangible Assets Acquired of $1.42 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 · last filed 2026-08-14

  • 60 DEGREES PHARMACEUTICALS, INC. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2026-06-30 was -$15.16K.
  • 60 DEGREES PHARMACEUTICALS, INC. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2026-03-31 was $16.58K.
  • 60 DEGREES PHARMACEUTICALS, INC. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2025-12-31 was $20.50K.
  • 60 DEGREES PHARMACEUTICALS, INC. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2023-12-31 was $0.00.
  • 60 DEGREES PHARMACEUTICALS, INC. noncash or part noncash acquisition, intangible assets acquired for fiscal 2025 was $24.29K.
  • 60 DEGREES PHARMACEUTICALS, INC. noncash or part noncash acquisition, intangible assets acquired for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
  • 60 DEGREES PHARMACEUTICALS, INC. noncash or part noncash acquisition, intangible assets acquired for fiscal 2023 was $33.90K.
Period endNoncash or Part Noncash Acquisition, Intangible Assets Acquired 3 monthNoncash or Part Noncash Acquisition, Intangible Assets Acquired 6 monthNoncash or Part Noncash Acquisition, Intangible Assets Acquired 9 monthNoncash or Part Noncash Acquisition, Intangible Assets Acquired 12 month
2026-06-30-$15.16K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
$1.42K
10-Q · filed 2026-08-14
$21.91K
derived: sum of 3 quarters · filed 2026-08-14
2026-03-31$16.58K
10-Q · filed 2026-05-15
$37.07K
derived: sum of 2 quarters · filed 2026-05-15
2025-12-31$20.50K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$24.29K
10-K · filed 2026-03-30
2025-09-30$3.80K
10-Q · filed 2025-11-13
2024-12-31$0.00
10-K · filed 2026-03-30
2023-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27
$0.00
derived: sum of 2 quarters · filed 2025-03-27
$33.90K
10-K · filed 2025-03-27
2023-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
$33.90K
10-Q · filed 2024-11-14
2023-06-30$33.90K
10-Q · filed 2024-08-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lakewood-Amedex Biotherapeutics Inc. (LABT)United States$0.004B
REVELATION BIOSCIENCES, INC. (REVB)United States$0.004B
HCW Biologics Inc. (HCWB)United States$0.004B-6.15
Cadrenal Therapeutics, Inc. (CVKD)United States$0.004B-0.90
Onconetix, Inc. (ONCO)United States$0.004B
Aptevo Therapeutics Inc. (APVO)United States$0.003B
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)United States$0.005B
Dermata Therapeutics, Inc. (DRMA)United States$0.005B-0.62
Sunshine Biopharma Inc. (SBFM)$0.003B
AMARIN CORP PLC\UK (AMRN)$0.005B-247.24